Navigation Links
PuraMed BioScience Discusses Potential for Patent Portfolio Acquisition
Date:5/30/2013

SCHOFIELD, Wis., May 30, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCBB:PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced an online interview to discuss recent developments, and the potential acquisition of a health and beauty products patent portfolio.

Highlights of the almost seven-minute interview, include:

  • Revenue Potential for LipiGesic® M Could Exceed $50 Million
  • Expanding Retail Chain-Store Distribution
  • Expansion into International Markets
  • Potential Patent Portfolio Acquisition Worth Millions
  • Market Capitalization Currently under $1 Million

Revenue Potential
Russ Mitchell , the Chairman and CEO of PuraMed BioScience, commented that with nearly 60 million Americans suffering from migraines the revenue potential for LipiGesic M, their over-the-counter migraine pain relief product, could generate over $50 million in sales annually by capturing just 1 percent of the migraine market.

Mr. Mitchell also discussed expanding distribution for their over-the-counter migraine pain reliever product, LipiGesic M, which is currently available in approximately 15,000 Walgreen's and CVS/pharmacy stores in all 50 states in the United States. According to Mr.Mitchell, he expects LipiGesic M to expand distribution into additional chains and wholesalers including all major retailers known to carry health and beauty products.

Off air, Mr. Mitchell said, "This expanded distribution would include mass merchandisers such as Wal-Mart and Target; food-store chains such as SuperValu, Kroger, and Safeway; as well as regional drugstore chains, which would add approximately another 21,000 stores."

In addition to US distribution, PuraMed BioScience has received its initial order from Columbia and has plans to expand to other Latin American countries as well as other regions around the world.

Patent Portfolio Acquisition
In the interview, Mr. Mitchell discussed current negotiations to acquire a patent portfolio of products in the anti-inflammatory, anti-bacterial, and anti-viral categories. Upon completion of the acquisition, PuraMed BioScience intends to license some of these patents to larger key manufacturers or bring these products to market directly. Mr. Mitchell commented, "Each one of those categories is huge, and has the potential to bring in many millions of dollars of additional revenue as these products get placed into the market."

To access the online interview please visit http://www.wallstreetnewscast.com/profile/pmbs.html

About PuraMed BioScience, Inc.
PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to LipiGesic M, www.lipiGesic.com, PuraMed BioScience plans to launch LipiGesic H for tension-type headaches and LipiGesic PM, which provides a remedy for insomnia and other sleep disorders. www.puramedbioscience.com

Forward-Looking Statements
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties that may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

Contact:
Melissa Diaz ,
South Street Media, Inc
Phone: (917) 937-8968
Email: info@southstreetmedia.com


'/>"/>
SOURCE PuraMed BioScience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. HUYA Bioscience International Engages In Partnership With Zhuhai Sanzao Science and Technology Industrial Park
9. Tethys Bioscience and Lose it! Announce a Strategic Partnership to Support Diabetes Prevention
10. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
11. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2018)... , ... December 07, 2018 , ... Nationally, it is ... that have dental insurance benefits that are seriously lacking and make it challenging to ... Dentistry believes that dental care should be accessible and affordable to everyone, with or ...
(Date:12/8/2018)... ... 2018 , ... Cardiologist Ernst von Schwarz, MD says that women can experience ... ignored completely by their doctors. “This can be especially dangerous in younger women who ... themselves on symptoms that are unique to women so they may become better advocates ...
(Date:12/6/2018)... , ... December 06, 2018 , ... Last year, 172 ... officials, 80% of those children had not gotten the vaccine. Vaccination is the first ... as flu shots reduce the severity of the illness if infected. Along with getting ...
Breaking Medicine Technology:
(Date:12/14/2018)... ... ... Bathing can be very dangerous for seniors and people suffering from loss ... bathroom for seniors 65 and older, according to The National Council of Aging. Ella's ... distributing walk-in tubs and bath accessories. Following these tips may help decrease the risk ...
(Date:12/13/2018)... (PRWEB) , ... December 13, 2018 , ... Ross A. ... the RealSelf Hall of Fame, an honor recognizing the highest-rated and most active doctors ... connect with medical aesthetic providers. Dr. Clevens has been named a “Distinguished Inductee,” a ...
(Date:12/13/2018)... ... December 13, 2018 , ... New research out of Roswell Park ... their diagnosis are significantly more likely to survive than those who are sedentary, adding ... a cancer prevention and treatment strategy. The results were published in a recent issue ...
(Date:12/13/2018)... ... December 13, 2018 , ... Women’s Excellence recently implemented a new online ... their questions answered. Women’s Excellence is proud to announce that the chat service ... be available during evening hours. , “This is the second time I have used ...
(Date:12/13/2018)... ... December 13, 2018 , ... FOR IMMEDIATE ... part of its commitment to providing more jobs in America, Fellow Health Partners ... Inc., a New York based medical business solutions company, today announced the launch ...
Breaking Medicine News(10 mins):